Advertisement
MDT vs SNN
Which Stock Would AI Choose? Medtronic (MDT) vs. Smith & Nephew (SNN) Stock Comparison
Key Takeaways
- Scale contrast: MDT is a diversified medical-device giant (roughly $113 billion market capitalization), while SNN is a more focused orthopaedics, sports medicine, and wound-care specialist (roughly $11 billion).
- Growth trajectory: Medtronic has raised its full-year organic revenue guidance, while Smith & Nephew recently lowered its 2026 revenue outlook to about 4% underlying growth.
- Momentum: Medtronic's cardiovascular franchise is accelerating, whereas Smith & Nephew is working through softness in U.S. orthopaedics and advanced wound bioactives.
- Income profile: Medtronic offers a higher dividend yield (about 3.2%) with 49 consecutive years of increases; Smith & Nephew yields lower but is also raising its payout.
- Relative performance: Both stocks have lagged broader markets over recent years, though their current drivers differ materially.
Introduction
Medtronic plc (MDT) and Smith & Nephew plc (SNN) are two prominent medical-technology companies operating in overlapping but distinct parts of the device industry. This stock comparison is relevant for investors weighing a large-cap, diversified healthcare name against a smaller, turnaround-focused specialist. Medtronic spans cardiovascular, neuroscience, medical-surgical, and robotics markets, while Smith & Nephew concentrates on orthopaedic reconstruction, sports medicine, ENT (ear, nose, and throat), and advanced wound management. Their recent market positioning diverges: Medtronic is reporting accelerating organic growth, while Smith & Nephew is navigating company-specific headwinds even as it protects profitability. Comparing the two helps clarify trade-offs between scale, growth momentum, dividend income, and turnaround risk.
MDT Overview and Recent Performance
Medtronic plc is a global medical-device leader headquartered in Dublin, Ireland, with operations spanning cardiovascular, neuroscience, medical-surgical, and diabetes-related therapies. In recent quarters, the company has reported its strongest enterprise revenue growth in roughly a decade. In its most recent fiscal quarter, revenue rose 13.7% year over year to nearly $9.8 billion, with cardiovascular revenue up 18.9% organically, driven by an 88% jump in cardiac ablation solutions. The company raised its full-year organic revenue growth guidance to a range of 7.25% to 7.75%.
Despite these improving fundamentals, the stock has underperformed: shares are down more than 7% so far in 2026 and off more than 30% over the past five years. The company has completed the spin-off of its diabetes business (MiniMed) and is investing heavily in its Hugo robotic-assisted surgery platform and targeted acquisitions, including CathWorks, Scientia Vascular, and SPR Therapeutics. A low beta of roughly 0.5x and a dividend yield near 3.2% underscore its defensive, income-oriented character.
SNN Overview and Recent Performance
Smith & Nephew plc is a British medical-technology company headquartered in Watford, England, operating across three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company has been executing a multi-year turnaround, most recently formalized in its "Rise" strategy aimed at simplifying its portfolio, reducing inventory, and improving shareholder returns. In fiscal 2025, revenue rose 6.1% to about $6.16 billion, with trading profit up 15.5%.
More recently, however, momentum has softened. First-half 2026 revenue grew just 2.3% on an underlying basis, and management reduced its full-year revenue outlook from around 6% to roughly 4% growth. Strength in sports medicine (up 8.6% in the quarter) and ENT has been offset by weakness in U.S. orthopaedics and advanced wound bioactives, where reimbursement changes have pressured results. The company has nonetheless maintained its profit-growth targets, citing efficiency savings and tariff refunds. The ADR trades near the low end of its 52-week range.
Trending AI Robots
For investors seeking a data-driven edge in navigating names like MDT and SNN, Tickeron's Trending AI Robots page offers a curated view of its marketplace. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only a select subset earns placement in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, historical performance, and the tickers they cover. The curated list surfaces the bots best suited to current market conditions, with some configurations generating a notable number of signals and achieving attractive win-rate and return metrics over their tracked periods. Because each robot applies a different approach, the page helps traders identify systems whose methodology aligns with their own objectives. Explore the Trending AI Robots section to review the currently featured bots and their live statistics.
Head-to-Head Comparison
The two companies differ fundamentally in business model. Medtronic is a broadly diversified platform with multiple large franchises and an expanding robotics and ablation pipeline, while Smith & Nephew is a more concentrated player whose fortunes hinge on orthopaedic recovery and wound-care dynamics. On growth drivers, Medtronic's cardiovascular portfolio and pulsed-field ablation are clear accelerants, whereas Smith & Nephew is leaning on sports medicine, ENT, and robotics (CORI) to offset orthopaedic softness.
Risk factors also diverge. Medtronic faces integration costs from its diabetes spin-off, robotics competition, and pricing pressure in neuroscience. Smith & Nephew contends with U.S. reimbursement changes for skin substitutes, a cementless-implant portfolio gap in knees, and China volume-based procurement (VBP) headwinds. On market sentiment, Medtronic carries a lower valuation (forward P/E (price-to-earnings) near 15) and a stronger dividend cushion, while Smith & Nephew offers a potential re-rating story if its turnaround gains traction. Neither name has delivered standout relative performance recently, but their catalysts are distinct.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward MDT in the current environment. Medtronic's combination of accelerating organic growth, raised guidance, a defensive low-beta profile, and a well-covered dividend suggests more consistent trend stability than SNN, which has recently revised its revenue outlook lower. That said, the verdict is probabilistic rather than definitive: Smith & Nephew's profit discipline and potential for orthopaedic recovery represent a meaningful, if less predictable, catalyst. Investors focused on momentum and income may find Medtronic's positioning comparatively more favorable, while those comfortable with turnaround risk may weigh Smith & Nephew's valuation reset differently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a Hold and SNN is a Hold.
MDT | SNN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 68 | 92 | |
PRICE GROWTH RATING 1..100 | 54 | 73 | |
P/E GROWTH RATING 1..100 | 57 | 86 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (3) in the Medical Specialties industry is in the same range as MDT (4). This means that SNN’s stock grew similarly to MDT’s over the last 12 months.
SNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MDT (100). This means that SNN’s stock grew similarly to MDT’s over the last 12 months.
MDT's SMR Rating (68) in the Medical Specialties industry is in the same range as SNN (92). This means that MDT’s stock grew similarly to SNN’s over the last 12 months.
MDT's Price Growth Rating (54) in the Medical Specialties industry is in the same range as SNN (73). This means that MDT’s stock grew similarly to SNN’s over the last 12 months.
MDT's P/E Growth Rating (57) in the Medical Specialties industry is in the same range as SNN (86). This means that MDT’s stock grew similarly to SNN’s over the last 12 months.
| MDT | SNN | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 50% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 55% | N/A |
| MACD ODDS (%) | 5 days ago 45% | N/A |
| TrendWeek ODDS (%) | 2 days ago 54% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 52% | 2 days ago 60% |
| Advances ODDS (%) | 5 days ago 54% | 5 days ago 58% |
| Declines ODDS (%) | 3 days ago 55% | 9 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 43% | 2 days ago 63% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green while SNN’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 4 TA indicator(s) are bullish while SNN’s TA Score has 4 bullish TA indicator(s).
- MDT’s TA Score: 4 bullish, 6 bearish.
- SNN’s TA Score: 4 bullish, 2 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а -1.54% price change this week, while SNN (@Medical/Nursing Services) price change was -0.37% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.19%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -2.76%.
Reported Earning Dates
MDT is expected to report earnings on Nov 24, 2026.
SNN is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement